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The insulin-like growth factor (IGF) signaling system plays a crucial role in human cancer
and the IGF-1 receptor (IGF-1R) is an attractive drug target against which a variety of
novel anti-tumor agents are being developed. Deregulation of the IGF signaling pathway
frequently occurs in human cancer and involves the establishment of autocrine loops
comprising IGF-1 or IGF-2 and/or IGF-1R over-expression. Epidemiologic studies have
documented a link between elevated IGF levels and the development of solid tumors, such
as breast, colon, and prostate cancer. Anti-cancer strategies targeting the IGF signaling
system involve two main approaches, namely neutralizing antibodies and small molecule
inhibitors of the IGF-1R kinase activity. There are numerous reports describing anti-tumor
activity of these agents in pre-clinical models of major human cancers. In addition, multiple
clinical trials have started to evaluate the safety and efﬁcacy of selected IGF-1R inhibitors, in
combination with standard chemotherapeutic regimens or other targeted agents in cancer
patients. In this mini review, I will discuss the role of the IGF signaling system in human
cancer and the main strategies which have been so far evaluated to target the IGF-1R.
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THE IGF/INSULIN FAMILY OF GROWTH FACTORS
The insulin-like growth factor (IGF)/insulin family of growth fac-
tors is an evolutionally conserved system which plays a crucial role
in the growth and development of many tissues and the regulation
of overall growth and metabolism. This system comprises three
receptors [insulin receptor (IR), IGF-1 receptor (IGF-1R), and
IGF-2/mannose 6-phosphate receptor (M-6-PR)], three ligands
(insulin, IGF-1, and IGF-2), and six known types of circulating
IGF-binding proteins (IGFBP1–6; Pollak et al., 2004; Pollak, 2008).
The IGF-1R is a receptor tyrosine kinase which is widely expressed
in many human tissues and cell types and is highly homologous
to the IR. However, these two receptors have distinct functions,
since the IGF-1R controls apoptosis, cell growth, and differenti-
ation, while the IR regulates physiological processes. The IGF-1R
is a heterotetrameric glycoprotein composed of two α and two β
subunits, post-transcriptionally linked by disulﬁde bonds. Activa-
tion of the IGF-1R is achieved by binding of its speciﬁc ligand to
the extracellular α subunits, which leads to autophosphorylation
of three tyrosine residues within the kinase domain of the IGF-1R
β subunit.
Insulin-like growth factors 1 and 2 are single-chain polypep-
tides with a high sequence homology to pro-insulin. The half-lives,
transportation, and bioavailability of the IGFs circulating at high
concentrations in the bloodstream and extracellular ﬂuids are
modulated by several high afﬁnity IGF-binding proteins (IGFBP1–
6). More than 99% of the circulating IGFs are bound to IGFBPs
and the IGFBPs themselves are tightly regulated by tissue speci-
ﬁcity, cell or matrix association, phosphorylation, and proteolysis
by various proteases (Baxter, 2000).
Both IGF-1 and IGF-2 interactwith the IGF-1R,although IGF-1
shows a much higher afﬁnity than IGF-2. The IGF-2 receptor
(M-6-PR), differs signiﬁcantly from the IGF-1R and does not
activate speciﬁc cellular responses. The ability of the highly homol-
ogous IGF-1R and IR to form hybrid receptors by dimerization
further increases the complexity of the signaling system. Such
IGF-1R/IR hybrid receptors have been reported to inﬂuence cell
responses by altering the afﬁnities of their growth factor lig-
ands (Pandini et al., 2002; Pollak, 2008; Gallagher and LeRoith,
2010). These hybrid receptors can stimulate cell proliferation,
especially in the case of the IR-A isoform, which has been found
over-expressed in cancer (Denley et al., 2003).
The main intracellular signaling pathways downstream of
the IGF-1R use the IR substrates-1 to -4 (IRS-1 to -4) and
the Src-homology collagen protein (Shc) isoforms as adapter
molecules. Phosphorylation of the IRS adapter molecules on
one hand triggers activation of the phosphoinositide 3-kinase
(PI3K)/Akt signaling pathway, whereas, on the other hand, the
Shc adapter activates signaling by the Ras/Raf/MEK/Erk signal-
ing pathway (Figure 1). Generally, signals controlled by the
IGF-1R have pleiotropic effects on cell behavior controlling
cell proliferation, differentiation, and cell migration, but also
regulating the apoptotic machinery (Pollak, 2008; Gallagher and
LeRoith, 2010).
THE ROLE OF THE IGF-1R IN HUMAN CANCER
In the past decades, a large body of evidence has arisen, supporting
a key role for IGF-1R signaling in various types of human cancers
(Pollak, 2008; Gallagher and LeRoith, 2010). A number of studies
performed in the last two decades have demonstrated a role for this
receptor in the transformation of cells, cancer cell proliferation, as
well as in metastatic events (Kaleko et al., 1990; Sell et al., 1994;
Scotlandi et al., 2002; Sachdev et al., 2004; Carboni et al., 2005).
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FIGURE 1 | Schematic representation of the IGF-1R, its ligands and the main intracellular signaling pathways activated.The two main classes of
experimental drugs against the receptor (antibodies and tyrosine kinase inhibitors) are also depicted.
While no recurrent cancer-speciﬁc mutations of the IGF-1R
or its ligands have been described to date, a plethora of studies
have provided evidence for a link between this signaling pathway
and the risk of developing cancer (Khandwala et al., 2000; Pollak,
2008; Gallagher and LeRoith, 2010). The most common ﬁndings
associated with deregulated IGF signaling are over-expression of
the IGF-1R or the establishment of autocrine or paracrine sig-
naling loops. While high expression levels of the IGF-1R have
been found in breast and colorectal cancer, autocrine signaling
loops are more common, and have been reported in a wide vari-
ety of human malignancies. Paracrine signaling has mainly been
described for breast cancer, where stromal cells have been shown
to produce IGF-1 and IGF-2. Population studies have further
highlighted the importance of IGF signaling in some of the most
common cancers (Guerreiro et al., 2006a; Pollak, 2008; Gallagher
and LeRoith, 2010). The published evidence from epidemiological
studies has revealed a correlation between elevated IGF-1 levels
and an increased risk of cancer diagnosis (Pollak et al., 2004; Guer-
reiro et al., 2006a; Pollak, 2008; Gallagher and LeRoith, 2010).
Although the population studies did not always come to the
same conclusions, systematic reviews of these results led to the
interpretation that circulating IGF-1 levels are indeed related to
a risk of several common cancers (Renehan et al., 2004). The
most signiﬁcant correlation between increased levels of IGF-1
and the risk of cancer diagnosis was found for prostate can-
cer, pre-menopausal breast cancer, and colorectal cancer (Wolk
et al., 1998; Ma et al., 1999; Giovannucci et al., 2000; Harman
et al., 2000; Kaaks et al., 2000; Stattin et al., 2000; Chan et al.,
2002; Palmqvist et al., 2002; Chen et al., 2009; Major et al., 2010;
Rinaldi et al., 2010). However, it should be noted that no signif-
icant overall associations were found between breast cancer and
common germline variation in IGF1 and other genes involved
in IGF-1 metabolism in a large, comprehensive study (Canzian
et al., 2010).
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In summary, mechanistic and epidemiological studies have
provided substantial information supporting a role for IGF signal-
ing and the IGF-1R in human cancers. The IGF-1R has emerged
as a promising target for the development of new therapeutic
approaches, which can be combined with other classical treatment
regimens.
STRATEGIES TO TARGET THE IGF-1R IN CANCER THERAPY
The IGF-1R can be inhibited through various experimental
approaches (Figure 1). I will focus the discussion on the two
approaches which are currently being evaluated in clinical trials:
(A) neutralizing antibodies and (B) small molecule inhibitors of
the IGF-1R tyrosine kinase activity.
NEUTRALIZING ANTIBODIES
A number of monoclonal antibodies have been developed to tar-
get the receptor itself, which bind to the extracellular domains of
the IGF-1R and block ligand binding. A feature common to all
anti-IGF-1R antibodies, probably more important than the block-
ing activity itself, is their ability to down-regulate of the IGF-1R
overtime by promoting internalization of the receptor. Receptor-
targeting antibodiesmight have important therapeutic advantages,
concerning both speciﬁcity and toxicity. A variety of fully human
anti-IGF-1R monoclonal antibodies have been characterized and
showed strong anti-tumor activity in vitro and in vivo (King and
Wong, 2012). Most IGF-1R antibodies which have been evalu-
ated in clinical trials so far have proven to be well tolerated (King
and Wong, 2012). A selection of the results published with these
molecules is described below.
AMG-479 (ganitumab; Amgen) is a fully human immunoglob-
ulin G1 (IgG1) against the IGF-1R (Beltran et al., 2009). AMG-479
blocks IGF-1 and IGF-2 binding to the IGF-1R without cross-
reacting with the IR and also inhibits the activation of IGF-1R
homodimers and IGF-1R/IR hybrids (Beltran et al., 2009). A
phase I study in patients with advanced solid malignancies or
non-Hodgkin’s lymphoma showed that AMG 479 can be admin-
istered safely and tumor responses were observed in patients
with Ewing/primitive neuroectodermal tumors and neuroen-
docrine tumors (Tolcher et al., 2009). The efﬁcacy and safety
of ganitumab combined with gemcitabine was investigated in
a randomized phase II trial in patients with metastatic pancre-
atic cancer (Kindler et al., 2012). The combination had tolerable
toxicity and showed trends toward improved survival rate and
overall survival (Kindler et al., 2012). Another phase II study
with ganitumab as a monotherapy in patients with metastatic
Ewing family tumors or desmoplastic small round cell tumors
showed that it waswell tolerated and demonstrated activity in both
tumor types (Tap et al., 2012). Several other phase II clinical trials
evaluating ganitumab, alone and in combination with other anti-
cancer agents, are ongoing in patients with various types of solid
tumors.
CP-751,871 (ﬁgitumumab; Pﬁzer) is a fully human IgG2 anti-
body which blocks binding of IGF-1 to its receptor, IGF-1-induced
receptor autophosphorylation and induces the down-regulationof
IGF-1R (Cohen et al., 2005; Gualberto, 2010). A phase I study in
patientswith refractory solid tumors showed that ﬁgitumumabhas
a favorable safety proﬁle and is well tolerated (Haluska et al., 2007).
A phase I study in patients with multiple myeloma conﬁrmed the
favorable proﬁle of this agent and some responses were reported
in patients treated with ﬁgitumumab in combination with dexam-
ethasone (Lacy et al., 2008). Another phase I study in patients with
sarcoma and Ewing’s sarcoma found ﬁgitumumab to be well toler-
ated and had anti-tumor activity in Ewing’s sarcoma (Olmos et al.,
2010). A phase Ib study tested ﬁgitumumab in combination with
docetaxel in patients with advanced solid tumors and found this
regimen to be well tolerated (Molife et al., 2010). A phase I trial of
the combination of everolimus and ﬁgitumumab was conducted
in patients with advanced sarcomas and other solid tumors (Quek
et al., 2011). The combination appeared safe and exhibited inter-
esting anti-tumor activity warranting further investigation (Quek
et al., 2011). In squamous cell carcinoma of the head and neck,
ﬁgitumumab showed no activity in a phase II trial as a single agent
(Schmitz et al., 2012). Although ﬁgitumumab induced a down-
regulation of the IGF-1R, an activation of the epidermal growth
factor receptor (EGFR) pathway was noted (Schmitz et al., 2012),
which may contribute to resistance to this agent. Despite these
results, two large-phase III trials investigating the addition of ﬁg-
itumumab to either carboplatin/paclitaxel (NCT00596830), or to
erlotinib (NCT00673049) in advanced non-small cell lung cancer
(NSCLC) patients were terminated after planned interim analysis
indicated futility.
IMC-A12 (cixutumumab; ImClone Systems Incorporated) is
a fully human monoclonal anti-IGF-1R IgG1 antibody, which
inhibits receptor activation, downstream signaling and also medi-
ates internalization and degradation of the receptor (Rowin-
sky et al., 2007). Although promising single-agent activity was
observed, the most impressive effects of targeting the IGF-1R
with IMC-A12 were observed when this agent was combined with
cytotoxic agents or other targeted therapeutics (Rowinsky et al.,
2007). The results of a phase II study of IMC-A12, with or without
cetuximab, in patients with refractory metastatic colorectal cancer
documented that IMC-A12 alone, or in combination with cetux-
imab, was insufﬁcient to warrant additional study in patients with
colorectal cancer refractory to EGFR inhibitors (Reidy et al., 2010).
IMC-A12 was evaluated in combination with the mammalian tar-
get of rapamycin (mTOR) inhibitor temsirolimus in patients with
refractory Ewing’s sarcoma family tumors (Naing et al., 2012). The
combination was well tolerated and showed preliminary evidence
of durable anti-tumor activity (Naing et al., 2012). Currently sev-
eral clinical trials are evaluating IMC-A12 as a single agent or
in combination with standard chemotherapy or other targeted
agents.
MK-0646 (dalotuzumab, h7C10; Merck) is a humanized IgG1
monoclonal antibody against the IGF-1R (Goetsch et al., 2005;
Scartozzi et al., 2010). Pre-clinical studies have demonstrated that
dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor
cell proliferation (Goetsch et al., 2005), IGF-1R autophosphoryla-
tion, and Akt phosphorylation (Wan et al., 2007; Cao et al., 2008;
Broussas et al., 2009; Scartozzi et al., 2010). Data from phase I
clinical trials demonstrated that dalotuzumab is safe, well toler-
ated and signiﬁcantly inhibits tumor proliferation (Scartozzi et al.,
2010; Atzori et al., 2011). A phase II study evaluated the safety and
efﬁcacy of MK-0646, as monotherapy in patients with metastatic,
well-differentiated neuroendocrine tumors (Reidy-Lagunes et al.,
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2012). MK-0646 was inactive as a single agent and thus further
studies of MK-0646 as a monotherapy in unselected neuroen-
docrine tumors are not warranted (Reidy-Lagunes et al., 2012).
Several clinical trials evaluating dalotuzumab, alone and in com-
bination with other anti-cancer agents, are ongoing in patients
with various types of solid tumors and in patients with multiple
myeloma.
R-1507 (robatumumab, Roche) is a fully humanized anti-IGF-
1R monoclonal antibody. In a panel of NSCLC cell lines predictive
biomarkers of response to R-1507 were investigated. While levels
of phospho-IGF-1R did not correlate with drug sensitivity, the
sensitive NSCLC cell lines displayed high levels of total IGF-1R
and higher copy numbers (Gong et al., 2009). Different studies
reported on the enhanced efﬁcacy of R-1507 in combination with
chemotherapy or other targeted agents in several tumors (Gong
et al., 2009; Kolb et al., 2010; Wojtalla et al., 2012). In a phase I
study of R-1507 in patients with advanced solid tumors R1507
was well tolerated and showed anti-tumor activity in patients
with solid neoplasms, in particular Ewing’s sarcoma (Kurzrock
et al., 2010). In a phase II study in patients with recurrent
or refractory Ewing’s sarcoma, R-1507 induced partial/complete
responses in only a subgroup of patients (Pappo et al., 2011). A
phase II study of R-1507 in combination with erlotinib was also
conducted in advanced-stage NSCLC. The combination did not
provide any beneﬁt in comparison to erlotinib alone in unselected
NSCLC patients (Ramalingam et al., 2011). Several clinical tri-
als evaluating R-1507, as single agent or in combination with
other drugs, are ongoing in patients with various types of solid
tumors.
Sch-717454 (19D12; Schering-Plough) is a humanized IgG1
anti-IGF-1R antibody which inhibits IGF binding and autophos-
phorylation of both IGF-1R/IGF-1R homodimers and IGF-1R/IR
heterodimers (but not IR homodimers; Wang et al., 2005). There
are no published results from clinical trials with Sch-717454 so far.
Four clinical trials have been performed with Sch-717454, one of
which is ongoing, one was completed and two terminated.
SMALL MOLECULE INHIBITORS OF THE IGF-1R TYROSINE
KINASE ACTIVITY
Several compounds with selectivity toward the IGF-1R tyro-
sine kinase have entered clinical trials (King and Wong, 2012).
Advances in characterization of the structural biology of the
insulin and IGF-1R were of great importance for the design of
speciﬁc IGF-1R inhibitors (De Meyts and Whittaker, 2002). IGF-
1R kinase inhibitors are likely candidates to become anti-IGF-1R
drugs. However, concerns regarding cross-reactivity with the IR
and toxicity, aswell as possiblemechanisms of resistance still ought
to be carefully addressed. A selection of results with smallmolecule
IGF-1R tyrosine kinase inhibitors (Figure 2) in pre-clinicalmodels
is presented below.
BMS-754807 (Bristol-Myers Squibb) is a potent and reversible
inhibitor of the IGF-1R/IR family kinases (Carboni et al., 2009;
Wittman et al., 2009). BMS-754807 effectively inhibited the
growth of a broad range of human tumor types in vitro and was
active in multiple xenograft tumor models (Carboni et al., 2009).
Combination studies with BMS-754807 revealed synergies when
the drug was combined with cytotoxic, hormonal, and targeted
agents (Carboni et al., 2009). In triple-negative breast cancers
BMS-754807 treatment resulted in tumor regression when com-
bined with docetaxel (Litzenburger et al., 2011). BMS-754807 was
tested by the Pediatric Preclinical Testing Program and in vivo
activity was most commonly observed in the neuroblastoma and
rhabdomyosarcoma panels (Kolb et al., 2011). In a subsequent
study, a BMS-754807-resistant rhabdomyosarcoma cell line model
was developed, which revealed that the platelet-derived growth
factor receptor alpha (PDGFRα) plays a role in acquired resistance
to BMS-754807. There are now several clinical trials (phase I and
II) ongoing with BMS-754807.
NVP-ADW742 and NVP-AEW541 (Novartis) are small molec-
ular weight kinase inhibitors of the IGF-1R, which are speciﬁc for
the IGF-1R at the cellular level (Garcia-Echeverria et al., 2004; Mit-
siades et al., 2004). NVP-ADW742 and NVP-AEW541 have been
extensively used in pre-clinical studies in a broad range of human
cancer models. However, these compounds were not considered
further for clinical development because of toxicity problems
observed during the pre-clinical testing phase. The potential of
NVP-ADW742 and NVP-AEW541 as single agents or in com-
bination with chemotherapeutic drugs human was investigated
in acute myeloid leukemia, Ewing’s sarcoma, medulloblastoma,
neuroblastoma, and small cell lung cancer (Scotlandi et al., 2005;
Warshamana-Greene et al., 2005; Guerreiro et al., 2006b; Tanno
et al., 2006; Doepfner et al., 2007; Tazzari et al., 2007; Urban-
ska et al., 2007). In atypical teratoid/rhabdoid tumor cells of the
central nervous system, NVP-AEW541 was shown to inhibit cell
proliferation and survival by blocking IGF-1R and IR activa-
tion by autocrine loops involving IGFs and insulin (Arcaro et al.,
2007). In colorectal cancer, studies with NVP-AEW541 suggested
that a combination therapy targeting both EGFR and IGF-1R
could be a promising approach (Kaulfuss et al., 2009). A study
in rhabdomyosarcoma also underscored the therapeutic poten-
tial of simultaneous targeting of IGF-1R and human epidermal
growth factor receptor 2 (HER2) to abrogate resistance (Abraham
et al., 2011). In pediatric glioblastoma co-treatment of the PDGFR
inhibitor imatinib with NVP-AEW541 resulted in a highly syner-
gistic interaction in vitro and increased efﬁcacy in vivo (Bielen
et al., 2011).
OSI-906 (Astellas Pharma) is a potent, selective, and orally
bioavailable dual IGF-1R/IR kinase inhibitor which has demon-
strated in vivo efﬁcacy in tumor models and is currently in clinical
testing (Mulvihill et al., 2009). The activity of OSI-906 in combina-
tion with standard chemotherapies was documented in colorectal
cancer models (Flanigan et al., 2010). Simultaneous administra-
tion of OSI-906 and doxorubicin also signiﬁcantly enhanced the
anti-tumor effect of doxorubicin (Zeng et al., 2012). In human
tumor cells co-expressing IGF-1R and IR, it was reported that
co-targeting IGF-1R and IR with OSI-906 provides superior anti-
tumor efﬁcacy compared with targeting IGF-1R alone using a
neutralizing antibody (Buck et al., 2010). Another study described
predictive biomarkers for OSI-906 in colorectal cancer (Pitts et al.,
2010). Baseline gene expression data fromcell lines and xenografts,
in combination with IGF-1R detection by in situ hybridization and
KRAS mutational status, was able to accurately predict OSI-906
sensitivity (Pitts et al., 2010). There are now several clinical trials
(phase I and II) ongoing with OSI-906.
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FIGURE 2 | Chemical structures of the IGF-1R tyrosine kinase inhibitors discussed in this article.
CONCLUSION
The available data from the ﬁrst clinical trials with agents tar-
geting the IGF-1R have been positive enough to launch several
phase II and III trials in various human cancers. The IGF-1R anti-
bodies appear to have a favorable safety proﬁle and have been
demonstrated to reduce IGF-1R signaling in patients. Concern-
ing the IGF-1R tyrosine kinase inhibitors, the ﬁrst published data
from clinical trials are still awaited. There have been several cases
of responses in phase I and II trials with anti-IGF-1R antibod-
ies, but these agents will most likely not be useful in unselected
patient populations. In addition, some phase II and III trials have
been suspended or terminated, because of lack of efﬁcacy of the
antibodies (such as ﬁgitumumab in NSCLC). The identiﬁcation
of predictive biomarkers is of crucial importance for the further
development of anti-cancer therapies based on anti-IGF-1R
agents (King and Wong, 2012). In conclusion, there are multi-
ple challenges still ahead, including the multiplicity of potential
cancer indications and drug combinations, as well as the need of
biomarkers for resistance and sensitivity.
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